Gerard Acampora, PHARMACIST
Pharmacist · North Haven, CT
Gerard Acampora, PHARMACIST is a pharmacist with a practice address in North Haven, Connecticut, and NPI 1497102719, issued on May 17, 2016. Check the license (Connecticut PCT.0005412, as entered in NPPES) with the Connecticut board that licenses this profession; the Medicare figures below come from public CMS files.
- Name
- Gerard Acampora
- Credential
- PHARMACIST
- Primary taxonomy
- Pharmacist 183500000X
- License number
- PCT.0005412 CT
Self-reported in NPPES; status is on the state search - Practice location
- 278 Maple Ave, North Haven, CT 06473
- Phone
- (203) 239-2086
- Enumerated
- May 17, 2016
- Entity
- Type 1 · individual
Also registered at 278 Maple Ave
A shared address usually means a shared clinic or building; it does not show who employs whom.
- Lisa Awugah, PHARM.D.Pharmacist1588031264
Verify Gerard Acampora in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersWhich Connecticut board licenses this profession
Search for license PCT.0005412Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS, AOA, NCCPA, AANPNot checked
36% more Medicare Part D claims than the average pharmacist in 2024
173 Medicare Part D claims for 141 beneficiaries, against an average of 127 among the 28,933 providers of this specialty who prescribed in Part D. Brand-name drugs were 99% of claims.
Most prescribed
- Mresvia66 claims
- Shingrix63 claims
- Boostrix Tdap26 claims
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
32 pharmacist records list a North Haven practice address
They are 32 of the 539 NPPES records with a North Haven practice address, and 3,264 pharmacist records in Connecticut.
All 32 in North Haven → All 3,264 in Connecticut → Every provider in North Haven →
Other pharmacist records in Connecticut
- Christopher Abbott, PHARMDKensington, CT1306136569
- Razanne AbdallaBridgeport, CT1558719138
- Mismak Abebe, PHARMDStamford, CT1760874697
- Audrey Abelleira, PHARMDWest Haven, CT1831671577
- Jeffrey Aberle, PHARMD.Wethersfield, CT1245513555
- Darlene Able, RPHEnfield, CT1811908197
- Yasmeen Abouelhassan, RPHEast Lyme, CT1689268872
- Alaaeldin AboumirahMeriden, CT1134715667
- Amanda Abraham, RPHWest Hartford, CT1508323999
- Bino Abraham, PHARMACISTStamford, CT1740934538
Common questions
What is Gerard Acampora, PHARMACIST's NPI number?
Gerard Acampora, PHARMACIST's National Provider Identifier (NPI) is 1497102719, issued on May 17, 2016. An NPI identifies a provider in billing; it is not a license.
Where is Gerard Acampora, PHARMACIST located?
The NPPES record lists a practice address at 278 Maple Ave, North Haven, CT, 06473. Phone: (203) 239-2086. Providers update this record themselves, so call before visiting.
How can I verify Gerard Acampora, PHARMACIST's license?
NPPES lists Connecticut license number PCT.0005412, as entered by the provider. Search the Connecticut board that licenses this profession; the NPPES record confirms identity only.
How much does Gerard Acampora, PHARMACIST prescribe under Medicare Part D?
In 2024, Gerard Acampora, PHARMACIST had 173 Medicare Part D claims for 141 beneficiaries; the average among pharmacist prescribers was 127. Part D covers Medicare prescriptions only.
Source: CMS National Plan and Provider Enumeration System (NPPES), loaded Aug 27, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 27, 2026.